

# Steven L Roberds

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7504606/publications.pdf>

Version: 2024-02-01

54  
papers

6,187  
citations

186209

28  
h-index

182361

51  
g-index

56  
all docs

56  
docs citations

56  
times ranked

5573  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. <i>Epilepsy Research</i> , 2022, 181, 106890.	0.8	10
2	Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. <i>Pediatric Neurology</i> , 2021, 115, 21-27.	1.0	13
3	Epilepsy Community at an Inflection Point: Translating Research Toward Curing the Epilepsies and Improving Patient Outcomes. <i>Epilepsy Currents</i> , 2021, 21, 385-388.	0.4	3
4	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	1.0	230
5	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. <i>Neuropharmacology</i> , 2020, 180, 108297.	2.0	23
6	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 109, 39-46.	1.0	23
7	Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. <i>Epilepsia</i> , 2019, 60, 1721-1732.	2.6	37
8	Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. <i>Pediatric Neurology</i> , 2019, 96, 58-63.	1.0	21
9	Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.. <i>American Psychologist</i> , 2019, 74, 356-367.	3.8	9
10	The Impact of Psychiatric Symptoms on Tuberous Sclerosis Complex and Utilization of Mental Health Treatment. <i>Pediatric Neurology</i> , 2019, 91, 41-49.	1.0	7
11	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. <i>Epilepsy Research</i> , 2018, 148, 1-7.	0.8	25
12	Patient Voice in Rare Disease Drug Development and Endpoints. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 257-263.	0.8	7
13	Partnering to support the next generation of epilepsy researchers. <i>Epilepsy and Behavior</i> , 2017, 75, 258-260.	0.9	0
14	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. <i>Pediatric Neurology</i> , 2016, 60, 1-12.	1.0	43
15	Commentary on Asato et al., "Epilepsy and comorbidities" What are we waiting for? <i>Epilepsy and Behavior</i> , 2014, 34, 136.	0.9	1
16	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
17	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693
18	Discovery of Potent Inhibitors of Soluble Epoxide Hydrolase by Combinatorial Library Design and Structure-Based Virtual Screening. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1211-1222.	2.9	56

#	ARTICLE	IF	CITATIONS
19	Rapid, Computer Vision-Enabled Murine Screening System Identifies Neuropharmacological Potential of Two New Mechanisms. <i>Frontiers in Neuroscience</i> , 2011, 5, 103.	1.4	29
20	Oral Delivery of 1,3-Dicyclohexylurea Nanosuspension Enhances Exposure and Lowers Blood Pressure in Hypertensive Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 102, 453-458.	1.2	34
21	1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats. <i>Journal of Experimental Nanoscience</i> , 2007, 2, 239-250.	1.3	18
22	Circulating Succinate is Elevated in Rodent Models of Hypertension and Metabolic Disease&lt;sub>title /&gt;. <i>American Journal of Hypertension</i> , 2007, 20, 1209-15.	1.0	122
23	Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. <i>Nanoscale Research Letters</i> , 2007, 2, 291-296.	3.1	21
24	Exploring the Foundation of Genomics: A Northern Blot Reference set for the Comparative Analysis of Transcript Profiling Technologies. <i>Comparative and Functional Genomics</i> , 2004, 5, 584-595.	2.0	2
25	A cluster of novel serotonin receptor 3-like genes on human chromosome 3. <i>Gene</i> , 2003, 319, 137-148.	1.0	88
26	ANALYSIS OF NOVEL DISEASE-RELATED GENES IN BRONCHIAL ASTHMA. <i>Cytokine</i> , 2002, 19, 287-296.	1.4	181
27	BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. <i>Human Molecular Genetics</i> , 2001, 10, 1317-1324.	1.4	644
28	Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. <i>Annals of Neurology</i> , 2001, 50, 730-740.	2.8	128
29	Applying genomics tools to identify therapeutic targets for asthma. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 1301-1312.	1.9	0
30	A 5â€² Dystrophin Duplication Mutation Causes Membrane Deficiency of -Dystroglycan in a Family with X-linked Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 3175-3188.	0.9	49
31	Immunogold localization of adhalin, Î±-dystroglycan and laminin in normal and dystrophic skeletal muscle. <i>Biochemical Society Transactions</i> , 1996, 24, 274S-274S.	1.6	0
32	CLINICAL AND MOLECULAR PATHOLOGICAL FEATURES OF SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY IN SAUDI ARABIA. <i>Developmental Medicine and Child Neurology</i> , 1996, 38, 262-270.	1.1	12
33	The Expression of Dystrophin-associated Glycoproteins During Skeletal Muscle Degeneration and Regeneration. An Immunofluorescence Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 557-569.	0.9	22
34	Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. <i>Nature Genetics</i> , 1995, 10, 243-245.	9.4	192
35	Expression of Deletion-Containing Dystrophins in mdx Muscle: Implications for Gene Therapy and Dystrophin Function. <i>Pediatric Research</i> , 1995, 37, 693-700.	1.1	11
36	Non-muscle alpha-dystroglycan is involved in epithelial development.. <i>Journal of Cell Biology</i> , 1995, 130, 79-91.	2.3	179

#	ARTICLE	IF	CITATIONS
37	A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. <i>Human Molecular Genetics</i> , 1995, 4, 1163-1167.	1.4	75
38	Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. <i>Neuron</i> , 1995, 15, 115-126.	3.8	202
39	Adhalin mRNA and cDNA sequence are normal in the cardiomyopathic hamster. <i>FEBS Letters</i> , 1995, 364, 245-249.	1.3	8
40	Adhalin gene polymorphism. <i>Human Molecular Genetics</i> , 1994, 3, 2269-2269.	1.4	8
41	A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. <i>Cell</i> , 1994, 77, 663-674.	13.5	361
42	Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. <i>Cell</i> , 1994, 78, 625-633.	13.5	463
43	Î±-Dystroglycan deficiency correlates with elevated serum creatine kinase and decreased muscle contraction tension in golden retriever muscular dystrophy. <i>FEBS Letters</i> , 1994, 350, 173-176.	1.3	13
44	Abnormal expression of laminin suggests disturbance of sarcolemma-extracellular matrix interaction in Japanese patients with autosomal recessive muscular dystrophy deficient in adhalin.. <i>Journal of Clinical Investigation</i> , 1994, 94, 601-606.	3.9	27
45	Molecular Biology of the Voltage-Gated Potassium Channels of the Cardiovascular System. <i>Journal of Cardiovascular Electrophysiology</i> , 1993, 4, 68-80.	0.8	67
46	Chromosomal mapping in the mouse of eight K <sup>+</sup> -channel-genes representing the four Shaker-like subfamilies Shaker, Shab, Shaw, and Shal. <i>Genomics</i> , 1993, 18, 568-574.	1.3	34
47	Clustering and immobilization of acetylcholine receptors by the 43-kD protein: a possible role for dystrophin-related protein.. <i>Journal of Cell Biology</i> , 1993, 123, 729-740.	2.3	107
48	Genetic heterogeneity for Duchenne-like muscular dystrophy (DLMD) based on linkage and 50 DAG analysis. <i>Human Molecular Genetics</i> , 1993, 2, 1945-1947.	1.4	50
49	Heteromultimeric assembly of human potassium channels. Molecular basis of a transient outward current?. <i>Circulation Research</i> , 1993, 72, 1326-1336.	2.0	171
50	Developmental expression of cloned cardiac potassium channels. <i>FEBS Letters</i> , 1991, 284, 152-154.	1.3	41
51	Functional characterization of RK5, a voltage-gated K <sup>+</sup> channel cloned from the rat cardiovascular system. <i>FEBS Letters</i> , 1991, 295, 211-213.	1.3	59
52	Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1798-1802.	3.3	226
53	Effect of the antiviral compound MDL 20,610 on some aspects of murine immune function. <i>International Journal of Immunopharmacology</i> , 1988, 10, 639-649.	1.1	1
54	Highly degenerate, inosine-containing primers specifically amplify rare cDNA using the polymerase chain reaction. <i>Nucleic Acids Research</i> , 1988, 16, 10932-10932.	6.5	111